LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 60

Search options

  1. Article ; Online: Comparability of C-Peptide Measurements - Current Status and Clinical Relevance.

    Hörber, Sebastian / Orth, Matthias / Fritsche, Andreas / Peter, Andreas

    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association

    2023  Volume 131, Issue 3, Page(s) 173–178

    Abstract: C-peptide is an increasingly used and established marker for beta cell function by assessing endogenous insulin secretion. Accurate and comparable C-peptide measurements are needed in clinical practice and research studies. For example, to calculate HOMA- ...

    Abstract C-peptide is an increasingly used and established marker for beta cell function by assessing endogenous insulin secretion. Accurate and comparable C-peptide measurements are needed in clinical practice and research studies. For example, to calculate HOMA-indices, the C-peptide/glucose ratio, and the classification of recently published novel subgroups of diabetes and prediabetes have used C-peptide measurements. Although the process for standardization of C-peptide measurements is advanced, its full implementation is still missing; therefore, the current status of the comparability of C-peptide measurements using different immunoassays is unclear. Here we compared five widely used C-peptide immunoassays on different analyzers (Abbott ALINITY i, DiaSorin Liaison XL, Roche Cobas e411, Siemens Healthineers ADVIA Centaur XPT, and Immulite 2000 XPi) using serum samples covering the clinically relevant C-peptide concentration range. Although all investigated immunoassays are traceable to the international reference reagent for C-peptide (NIBSC code: 84/510), results of C-peptide measurements showed significant differences between analyzers in the entire concentration range, especially with increasing C-peptide concentrations. The mean bias was largest (36.6%) between results of the immunoassays by Roche and Siemens Healthineers (ADVIA Centaur XPT), and both assays revealed large discrepancies compared to immunoassays by Abbott, DiaSorin, and Siemens Healthineers (Immulite 2000 XPi). In contrast, the three latter assays showed similar C-peptide results (mean bias: 2.3% to 4.2%). Consequently, C-peptide discrepancies might affect clinical diagnosis and the interpretation of study results. Therefore, there is an urgent need to implement and finalize the standardization process of C-peptide measurements to improve patient care and the comparability of research studies.
    MeSH term(s) Humans ; C-Peptide ; Clinical Relevance ; Immunoassay ; Reference Standards
    Chemical Substances C-Peptide
    Language English
    Publishing date 2023-01-11
    Publishing country Germany
    Document type Comparative Study ; Journal Article
    ZDB-ID 1225416-2
    ISSN 1439-3646 ; 0947-7349
    ISSN (online) 1439-3646
    ISSN 0947-7349
    DOI 10.1055/a-1998-6889
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: [No title information]

    Hörber, Sebastian / Orth, Matthias / Fritsche, Andreas / Peter, Andreas

    Experimental and Clinical Endocrinology & Diabetes

    2023  Volume 131, Issue 03, Page(s) 173–178

    Abstract: C-peptide is an increasingly used and established marker for beta cell function by assessing endogenous insulin secretion. Accurate and comparable C-peptide measurements are needed in clinical practice and research ...

    Abstract C-peptide is an increasingly used and established marker for beta cell function by assessing endogenous insulin secretion. Accurate and comparable C-peptide measurements are needed in clinical practice and research studies. For example, to calculate HOMA-indices, the C-peptide/glucose ratio, and the classification of recently published novel subgroups of diabetes and prediabetes have used C-peptide measurements. Although the process for standardization of C-peptide measurements is advanced, its full implementation is still missing; therefore, the current status of the comparability of C-peptide measurements using different immunoassays is unclear. Here we compared five widely used C-peptide immunoassays on different analyzers (Abbott ALINITY i, DiaSorin Liaison XL, Roche Cobas e411, Siemens Healthineers ADVIA Centaur XPT, and Immulite 2000 XPi) using serum samples covering the clinically relevant C-peptide concentration range. Although all investigated immunoassays are traceable to the international reference reagent for C-peptide (NIBSC code: 84/510), results of C-peptide measurements showed significant differences between analyzers in the entire concentration range, especially with increasing C-peptide concentrations. The mean bias was largest (36.6%) between results of the immunoassays by Roche and Siemens Healthineers (ADVIA Centaur XPT), and both assays revealed large discrepancies compared to immunoassays by Abbott, DiaSorin, and Siemens Healthineers (Immulite 2000 XPi). In contrast, the three latter assays showed similar C-peptide results (mean bias: 2.3% to 4.2%). Consequently, C-peptide discrepancies might affect clinical diagnosis and the interpretation of study results. Therefore, there is an urgent need to implement and finalize the standardization process of C-peptide measurements to improve patient care and the comparability of research studies.
    Keywords Diabetes, Prediabetes, Immunoassay, Standardization, Harmonization
    Language English
    Publishing date 2023-01-11
    Publisher Georg Thieme Verlag KG
    Publishing place Stuttgart ; New York
    Document type Article
    ZDB-ID 1225416-2
    ISSN 1439-3646 ; 0947-7349
    ISSN (online) 1439-3646
    ISSN 0947-7349
    DOI 10.1055/a-1998-6889
    Database Thieme publisher's database

    More links

    Kategorien

  3. Article ; Online: Evaluation of the first immunosuppressive drug assay available on a fully automated LC-MS/MS-based clinical analyzer suggests a new era in laboratory medicine.

    Hörber, Sebastian / Peter, Andreas / Lehmann, Rainer / Hoene, Miriam

    Clinical chemistry and laboratory medicine

    2020  Volume 59, Issue 5, Page(s) 913–920

    Abstract: Objectives: Due to its high specificity, liquid chromatography-tandem mass spectrometry (LC-MS/MS) is considered the gold standard in diagnostic areas such as therapeutic monitoring of immunosuppressive drugs (ISDs). However, many laboratories still ... ...

    Abstract Objectives: Due to its high specificity, liquid chromatography-tandem mass spectrometry (LC-MS/MS) is considered the gold standard in diagnostic areas such as therapeutic monitoring of immunosuppressive drugs (ISDs). However, many laboratories still rely on immunoassays for ISD quantification in a tradeoff between analytical performance and the advantages of fully automated analyzers - shorter turnaround times, greater ease of use, and 24/7 availability.
    Methods: The LC-MS/MS-based Thermo Scientific™ Cascadion™ SM Immunosuppressant Panel was evaluated for >6 months in the routine laboratory of a university hospital. We assessed the analytical performance of the panel and compared it to conventional LC-MS/MS as well as to immunoassays (cyclosporine A, sirolimus, tacrolimus (Siemens) and everolimus (Thermo Fisher)). In addition, both ISD panel and Cascadion analyzer were scrutinized with regards to, e.g., turnaround time, usability, and robustness.
    Results: All ISDs showed high linearity and precision (CV≤6%) and a good correlation with conventional LC-MS/MS. The mean deviation to the immunoassays was 17-19% and negative for all ISDs except everolimus with a positive 19% bias. No weak points were revealed when challenging assay and system with, e.g., high haematocrit, sedimented whole blood or priority samples. The Cascadion integrated well into our 24/7 routine and could easily be operated simultaneously with several other analyzers by technical staff without LC-MS experience.
    Conclusions: The ISD panel showed excellent analytical performance and demonstrated that a fully automated LC-MS-based analysis starting from primary samples is feasible, suggesting that LC-MS could become an integral part of 24/7 diagnostics in the near future.
    MeSH term(s) Chromatography, Liquid ; Drug Monitoring ; Everolimus ; Humans ; Immunosuppressive Agents ; Laboratories ; Pharmaceutical Preparations ; Tacrolimus ; Tandem Mass Spectrometry
    Chemical Substances Immunosuppressive Agents ; Pharmaceutical Preparations ; Everolimus (9HW64Q8G6G) ; Tacrolimus (WM0HAQ4WNM)
    Language English
    Publishing date 2020-10-19
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 1418007-8
    ISSN 1437-4331 ; 1434-6621 ; 1437-8523
    ISSN (online) 1437-4331
    ISSN 1434-6621 ; 1437-8523
    DOI 10.1515/cclm-2020-0848
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Evaluation of a laboratory-based high-throughput SARS-CoV-2 antigen assay.

    Hörber, Sebastian / Drees, Christoph / Ganzenmueller, Tina / Schmauder, Kristina / Peter, Silke / Biskup, Dirk / Peter, Andreas

    Clinical chemistry and laboratory medicine

    2022  Volume 60, Issue 9, Page(s) 1478–1485

    Abstract: Objectives: Antigen tests are an essential part of SARS-CoV-2 testing strategies. Rapid antigen tests are easy to use but less sensitive compared to nucleic acid amplification tests (NAT) and less suitable for large-scale testing. In contrast, ... ...

    Abstract Objectives: Antigen tests are an essential part of SARS-CoV-2 testing strategies. Rapid antigen tests are easy to use but less sensitive compared to nucleic acid amplification tests (NAT) and less suitable for large-scale testing. In contrast, laboratory-based antigen tests are suitable for high-throughput immunoanalyzers. Here we evaluated the diagnostic performance of the laboratory-based Siemens Healthineers SARS-CoV-2 Antigen (CoV2Ag) assay.
    Methods: In a public test center, from 447 individuals anterior nasal swab specimens as well as nasopharyngeal swab specimens were collected. The nasal swab specimens were collected in sample inactivation medium and measured using the CoV2Ag assay. The nasopharyngeal swab specimens were measured by RT-PCR. Additionally, 9,046 swab specimens obtained for screening purposes in a tertiary care hospital were analyzed and positive CoV2Ag results confirmed by NAT.
    Results: In total, 234/447 (52.3%) participants of the public test center were positive for SARS-CoV-2-RNA. Viral lineage B1.1.529 was dominant during the study. Sensitivity and specificity of the CoV2Ag assay were 88.5% (95%CI: 83.7-91.9%) and 99.5% (97.4-99.9%), respectively. Sensitivity increased to 93.7% (97.4-99.9%) and 98.7% (97.4-99.9%) for swab specimens with cycle threshold values <30 and <25, respectively. Out of 9,046 CoV2Ag screening tests from hospitalized patients, 21 (0.2%) swab specimens were determined as false-positive by confirmatory NAT.
    Conclusions: Using sample tubes containing inactivation medium the laboratory-based high-throughput CoV2Ag assay is a very specific and highly sensitive assay for detection of SARS-CoV-2 antigen in nasal swab specimens including the B1.1.529 variant. In low prevalence settings confirmation of positive CoV2Ag results by SARS-CoV-2-RNA testing is recommended.
    MeSH term(s) COVID-19/diagnosis ; COVID-19 Testing ; Clinical Laboratory Techniques/methods ; Humans ; RNA ; SARS-CoV-2 ; Sensitivity and Specificity
    Chemical Substances RNA (63231-63-0)
    Language English
    Publishing date 2022-06-14
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 1418007-8
    ISSN 1437-4331 ; 1434-6621 ; 1437-8523
    ISSN (online) 1437-4331
    ISSN 1434-6621 ; 1437-8523
    DOI 10.1515/cclm-2022-0360
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Impact of breastfeeding duration on coagulation in women with and without history of gestational diabetes mellitus.

    Fritsche, Louise / Löffler, Dorina / Kantartzis, Konstantinos / Flehmig, Gesine / Roden, Michael / Fritsche, Andreas / Birkenfeld, Andreas L / Peter, Andreas / Heni, Martin / Hörber, Sebastian

    The Journal of clinical endocrinology and metabolism

    2024  

    Abstract: Objective: Breastfeeding is associated with a reduced maternal risk for cardiovascular diseases. Since the underlying mechanisms are still poorly understood, we here examined the impact of breastfeeding on the plasmatic coagulation system in women with ... ...

    Abstract Objective: Breastfeeding is associated with a reduced maternal risk for cardiovascular diseases. Since the underlying mechanisms are still poorly understood, we here examined the impact of breastfeeding on the plasmatic coagulation system in women with and without history of gestational diabetes mellitus (GDM).
    Methods: 76 participants of the German Gestational Diabetes Study (PREG; NCT04270578) were examined 14 [interquartile range: 12-26] months after delivery with a 5-point oral glucose tolerance test. Global coagulation tests, prothrombotic coagulation proteins (FII/FVII/FVIII/FIX), antithrombotic proteins (antithrombin, protein C/S) and endothelial markers (von-Willebrand-factor and PAI-1) were determined. The Framingham Risk Score was used to estimate the 10-year cardiovascular risk. The impact of breastfeeding duration on coagulation was analyzed using multivariable linear models.
    Results: The mean duration of breastfeeding was 11 [7-14] months. Overall, longer duration of breastfeeding was associated with lower cardiovascular risk (Framingham Risk Score, p=0.05) and was negatively associated with FIX (p=0.018). We detected an interaction between previous GDM and breastfeeding duration for FIX (pInteraction=0.017): only in women with GDM history was the duration of breastfeeding negatively associated with FIX activity (p=0.016). This association persisted in statistical models adjusted for age, body-mass index, insulin sensitivity, and C-reactive protein. The duration of breastfeeding was not associated with anticoagulant proteins and endothelial markers.
    Conclusion: Longer duration of breastfeeding is associated with lower cardiovascular risk and an improved coagulation profile. Women with GDM history appear to benefit particularly from prolonged breastfeeding.
    Language English
    Publishing date 2024-03-15
    Publishing country United States
    Document type Journal Article
    ZDB-ID 3029-6
    ISSN 1945-7197 ; 0021-972X
    ISSN (online) 1945-7197
    ISSN 0021-972X
    DOI 10.1210/clinem/dgae172
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Harmonization of immunoassays for biomarkers in diabetes mellitus.

    Hörber, Sebastian / Achenbach, Peter / Schleicher, Erwin / Peter, Andreas

    Biotechnology advances

    2019  Volume 39, Page(s) 107359

    Abstract: Harmonization of biomarkers is important for the comparability of laboratory results as it allows the definition of universal reference values and clinical decision limits. In diabetology, immunoassays are widely used to determine HbA1c, C-peptide, ... ...

    Abstract Harmonization of biomarkers is important for the comparability of laboratory results as it allows the definition of universal reference values and clinical decision limits. In diabetology, immunoassays are widely used to determine HbA1c, C-peptide, insulin, and autoantibodies to beta cell proteins, which are essential biomarkers for the diagnosis and classification of diabetes mellitus. Furthermore, as large clinical studies have identified HbA1c as a predictor for the development of diabetic complications, HbA1c has evolved as the general treatment target. For decades, the use of non-harmonized assays caused confusion. After the standardization of HbA1c, the worldwide comparability improved and increased the confidence in this laboratory biomarker. Insulin and C-peptide are not only valuable biomarkers to assess beta-cell function, but may also be used to evaluate insulin resistance, a metabolic feature of type 2 diabetes often occurring before its manifestation. Long-lasting efforts led to substantial improvements in the harmonization process of C-peptide assays, but harmonization of insulin assays is still ongoing. Therefore, C-peptide is now sometimes used as a surrogate biomarker for insulin. Furthermore, autoantibodies against beta cell components are important biomarkers for the accurate differentiation of type 1, type 2, and other special types of diabetes. Owing to the heterogeneity of these autoantibodies against beta cell proteins, harmonization is very difficult to achieve. International efforts are in progress to harmonize the current assays, as the presence of autoantibodies against beta cell proteins predicts the development of type 1 diabetes in early life. In conclusion, clinical studies linking diagnosis, classification, prediction, and treatment to laboratory values of the respective biomarkers need to be harmonized to avoid misdiagnosis and incorrect clinical decisions, thus improving patient care and safety.
    MeSH term(s) Biomarkers ; C-Peptide ; Diabetes Mellitus ; Humans ; Immunoassay ; Insulin
    Chemical Substances Biomarkers ; C-Peptide ; Insulin
    Language English
    Publishing date 2019-02-23
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 47165-3
    ISSN 1873-1899 ; 0734-9750
    ISSN (online) 1873-1899
    ISSN 0734-9750
    DOI 10.1016/j.biotechadv.2019.02.015
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Evaluation of the Atellica COAG 360 coagulation analyzer in a central laboratory of a maximum care hospital.

    Hörber, Sebastian / Lehmann, Rainer / Peter, Andreas

    International journal of laboratory hematology

    2019  Volume 42, Issue 1, Page(s) 28–36

    Abstract: Introduction: Fully-automated coagulation analyzers are key components of a high-throughput central laboratory. The novel Atellica COAG 360 (Siemens Healthineers) is a high-volume coagulation analyzer approved for hemostasis diagnostics. The aim of the ... ...

    Abstract Introduction: Fully-automated coagulation analyzers are key components of a high-throughput central laboratory. The novel Atellica COAG 360 (Siemens Healthineers) is a high-volume coagulation analyzer approved for hemostasis diagnostics. The aim of the study was to evaluate the analytical performance of this coagulation analyzer in a central laboratory.
    Methods: Intra (n = 10)- and inter (n = 20)-assay precision of the Atellica COAG 360 was determined using commercially available control samples. Patient samples (n = 74-104) were used for comparison analyses with the Sysmex CS-5100 (Siemens Healthineers). Effects of visual interferences on coagulation testing were assessed and the sample throughput rate of the Atellica COAG 360 was determined.
    Results: Intra- and inter-assay precision of the Atellica COAG 360 showed coefficient of variations (CVs) < 5% for most of the coagulation parameters comparable to CVs of the Sysmex CS-5100. Passing-Bablok and Bland-Altman analyses revealed high correlation and good agreement between both coagulation analyzers in determination of coagulation parameters. Results of coagulation measurements determined in optically abnormal samples were comparable between the Atellica COAG 360 and the Sysmex CS-5100 and were confirmed by mechanical measurements on a STart Max (Stago Diagnostics) coagulation analyzer. A sample throughput rate of about 190 tests per hour in a routine setting including five coagulation parameters was determined for the Atellica COAG 360 integrated in a total laboratory automation system.
    Conclusion: The Atellica COAG 360 provides high analytical performance as high-throughput analyzer for routine and specific coagulation parameters and is suitable to be connected to a total laboratory automation.
    MeSH term(s) Adult ; Blood Coagulation ; Blood Coagulation Tests/instrumentation ; Blood Coagulation Tests/methods ; Female ; Humans ; Male ; Reproducibility of Results
    Language English
    Publishing date 2019-11-26
    Publishing country England
    Document type Clinical Trial ; Journal Article
    ZDB-ID 2268590-X
    ISSN 1751-553X ; 1751-5521 ; 0141-9854
    ISSN (online) 1751-553X
    ISSN 1751-5521 ; 0141-9854
    DOI 10.1111/ijlh.13119
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: Effects of Long-Term Storage on Serum Free Light Chain Stability.

    Hörber, Sebastian / Klein, Reinhild / Peter, Andreas

    Clinical laboratory

    2019  Volume 65, Issue 5

    Abstract: Background: Determination and quantification of serum free light chains (FLC) is essential for the diagnosis and monitoring of patients with monoclonal gammopathies. Currently, the Freelite assay (The Binding Site, United Kingdom) and the N Latex FLC ... ...

    Abstract Background: Determination and quantification of serum free light chains (FLC) is essential for the diagnosis and monitoring of patients with monoclonal gammopathies. Currently, the Freelite assay (The Binding Site, United Kingdom) and the N Latex FLC assay (Siemens Healthineers, Germany) are available for FLC determination. Data concerning stability of FLC following long-term storage are limited. Therefore, the aim of the present study is to investigate the stability of FLC in frozen samples determined by the N latex FLC assay.
    Methods: One hundred eighty-eight serum samples from 47 patients with monoclonal gammopathies were analyzed at the beginning and after long-term storage (-20°C, 193 - 568 days). Serum free light chain kappa (κFLC) and lambda (λFLC) concentrations were measured, and the corresponding kappa/lambda (κ/λ FLC) ratios were calculated. All samples were analyzed with the N latex FLC assay on a single BNII System.
    Results: Comparison analyses between fresh and stored samples revealed very strong correlations for the determination of κFLC (r = 0.993), λFLC (r = 0.998) and the calculated κ/λ FLC ratio (r = 0.997). Median percentage changes of κFLC (-0.5%) and λFLC (-0.8%) measurements and the calculated κ/λ FLC ratios (-3.7%) were within the calculated analytical imprecision of the FLC assay. Changes of κFLC (r = 0.17, p = 0.02) and λFLC (r = 0.28, p < 0.01) concentrations and of the κ/λ FLC ratio (r = 0.18, p = 0.01) over time were very weak, but statistically significant.
    Conclusions: Serum free light chains in serum samples are sufficiently stable following long-term frozen storage and are therefore suitable to be measured with the N Latex FLC assay.
    MeSH term(s) Blood Preservation/methods ; Cryopreservation/methods ; Humans ; Immunoglobulin Light Chains/blood ; Immunoglobulin Light Chains/chemistry ; Immunoglobulin kappa-Chains/blood ; Immunoglobulin kappa-Chains/chemistry ; Immunoglobulin lambda-Chains/blood ; Immunoglobulin lambda-Chains/chemistry ; Latex/chemistry ; Paraproteinemias/blood ; Paraproteinemias/diagnosis ; Protein Stability ; Reproducibility of Results ; Time Factors
    Chemical Substances Immunoglobulin Light Chains ; Immunoglobulin kappa-Chains ; Immunoglobulin lambda-Chains ; Latex
    Language English
    Publishing date 2019-05-21
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 1307629-2
    ISSN 1433-6510 ; 0941-2131
    ISSN 1433-6510 ; 0941-2131
    DOI 10.7754/Clin.Lab.2018.181107
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Harmonization of immunoassays for biomarkers in diabetes mellitus

    Hörber, Sebastian / Peter Achenbach / Erwin Schleicher / Andreas Peter

    Biotechnology advances. 2019 Feb. 21,

    2019  

    Abstract: Harmonization of biomarkers is important for the comparability of laboratory results as it allows the definition of universal reference values and clinical decision limits. In diabetology, immunoassays are widely used to determine HbA1c, C-peptide, ... ...

    Abstract Harmonization of biomarkers is important for the comparability of laboratory results as it allows the definition of universal reference values and clinical decision limits. In diabetology, immunoassays are widely used to determine HbA1c, C-peptide, insulin, and autoantibodies to beta cell proteins, which are essential biomarkers for the diagnosis and classification of diabetes mellitus. Furthermore, as large clinical studies have identified HbA1c as a predictor for the development of diabetic complications, HbA1c has evolved as the general treatment target. For decades, the use of non-harmonized assays caused confusion. After the standardization of HbA1c, the worldwide comparability improved and increased the confidence in this laboratory biomarker. Insulin and C-peptide are not only valuable biomarkers to assess beta-cell function, but may also be used to evaluate insulin resistance, a metabolic feature of type 2 diabetes often occurring before its manifestation. Long-lasting efforts led to substantial improvements in the harmonization process of C-peptide assays, but harmonization of insulin assays is still ongoing. Therefore, C-peptide is now sometimes used as a surrogate biomarker for insulin. Furthermore, autoantibodies against beta cell components are important biomarkers for the accurate differentiation of type 1, type 2, and other special types of diabetes. Owing to the heterogeneity of these autoantibodies against beta cell proteins, harmonization is very difficult to achieve. International efforts are in progress to harmonize the current assays, as the presence of autoantibodies against beta cell proteins predicts the development of type 1 diabetes in early life. In conclusion, clinical studies linking diagnosis, classification, prediction, and treatment to laboratory values of the respective biomarkers need to be harmonized to avoid misdiagnosis and incorrect clinical decisions, thus improving patient care and safety.
    Keywords autoantibodies ; biomarkers ; c-peptide ; clinical trials ; diabetic complications ; immunoassays ; insulin resistance ; insulin-dependent diabetes mellitus ; islets of Langerhans ; noninsulin-dependent diabetes mellitus ; normal values ; patient care ; prediction ; proteins
    Language English
    Dates of publication 2019-0221
    Size p. .
    Publishing place Elsevier Inc.
    Document type Article
    Note Pre-press version
    ZDB-ID 47165-3
    ISSN 0734-9750
    ISSN 0734-9750
    DOI 10.1016/j.biotechadv.2019.02.015
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  10. Article: Der Weg zur richtigen Diagnose

    Hörber, Sebastian / Peter, Andreas

    Diabetes aktuell

    2018  Volume 16, Issue 05, Page(s) 180–181

    Abstract: Labormedizinische Bestimmungen spielen eine entscheidende Rolle bei der Diagnose, Therapiekontrolle und Prognoseeinschätzung des Diabetes mellitus. Bestimmt werden können Nüchternplasmaglukose, Gelegenheitsplasmaglukose, 2h-Plasmaglukose und der HbA: 1c! ...

    Abstract Labormedizinische Bestimmungen spielen eine entscheidende Rolle bei der Diagnose, Therapiekontrolle und Prognoseeinschätzung des Diabetes mellitus. Bestimmt werden können Nüchternplasmaglukose, Gelegenheitsplasmaglukose, 2h-Plasmaglukose und der HbA: 1c
    Wert. Dabei ist es wichtig die Vor- und Nachteile der verschiedenen Methoden zu kennen.:
    Language German
    Publishing date 2018-08-01
    Publisher © Georg Thieme Verlag
    Publishing place Stuttgart ; New York
    Document type Article
    ZDB-ID 2225026-8
    ISSN 1864-1733 ; 1861-6089 ; 1617-0482
    ISSN (online) 1864-1733
    ISSN 1861-6089 ; 1617-0482
    DOI 10.1055/a-0655-5752
    Database Thieme publisher's database

    More links

    Kategorien

To top